PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.

類似資料

• Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
  著者:: Naseema Gangat, 等
  出版事項: (2022-06-01)
• Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
  著者:: Naseema Gangat, 等
  出版事項: (2022-12-01)
• Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
  著者:: Naseema Gangat, 等
  出版事項: (2023-03-01)
• Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
  著者:: Isla M. Johnson, 等
  出版事項: (2025-02-01)
• CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
  著者:: Saubia Fathima, 等
  出版事項: (2026-04-01)